Pharma Report 2012: Get Back in Shape

Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

11    Sanofi    $11.8    down 3.3%
Global revenue: $43.8B (6th); up 3.3%

R&D spend: $6.7B (6th), up 11.7%; 15.3% of rev.

Top brands: Lantus ($2.3B); Eloxatin ($806M); Lovenox ($633M); Taxotere ($243M); Plavix ($196M)

Planned launches: Teriflunomide (MS), visamerin (VTE), Lemtrada (MS), lixisenatide (diab.)

Promotional spend: $477M (12th); 4.0% of rev.

Patent expirations: Plavix (2012), Multaq (2014), Actonel (2014)

The diabetes medication merchant said in February that it expects business to fall off between 12% and 15% this year, as it weathers the aftershocks of patent losses on Lovenox, Ambien CR, Taxotere and Plavix. But it hopes to add diabetes treatment lixisenatide, a GLP-1 agonist scheduled to be filed this year. The GLP-1 field is a crowded one; Sanofi could bump up against Amylin's newcomer, Bydureon. Despite the uncertainty, Sanford Bernstein analyst Tim Anderson praised the company, in part because its patent cliff levels off next year.

Back to first page

Page 11 of 21
You must be a registered member of MMM to post a comment.
close

Next Article in Features

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters